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Background: Haemodialysis is the most common treatment method in Australia for
individuals requiring renal replacement therapy. Although it is known that the residual renal
function in these patients has many advantages for their overall health outcomes and that
the residual urine volume production is also declining over time, it is unknown how fast this
functional decline occurs when patients are embarking on their ﬁrst year on haemodialysis.
Aim: This scoping review sought to determine if the functional decline in renal residual
function in the ﬁrst year of haemodialysis has been previously investigated, documented
or quantiﬁed.
Method: The scoping review was performed using variety of nursing and medical
databases comprising MEDLINE, Embase, Web of Science and CINAHL Plus with Full Text.
Results: The decline of renal residual function in patients on Peritoneal dialysis over the
ﬁrst year of treatment has previously been described, but not in detail for patients receiving
haemodialysis. There is a paucity of knowledge how fast residual urine production can
decline in patients receiving haemodialysis during their ﬁrst year of treatment. A PRISMA
checklist has been used to validate the results of this scoping review.
Conclusions: The extended preservation of renal residual function in patients on
haemodialysis is crucial for their survival and may have a positive impact on their quality
of life. An observational study is needed to examine how fast the functional decrease of the
residual urine production function within patients receiving haemodialysis generally
occurs. This information could prove to be useful in the context of treatment goals and
could inform clinical practice.
Keywords: renal residual function, chronic kidney disease, haemodialysis, quality of life, ﬂuid assessment
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signiﬁcant information for clinicians and patients to lessen
disease burden and improve disease management.
Although several studies have described the functional
decline of the residual renal function in patients using PD (21,
22), there is a paucity of knowledge of the rate of the same
functional decline in HD patients during their ﬁrst year of
treatment. With HD being the most common renal
replacement therapy (RRT) modality in Australia (78% in year
2018) (23), this underscores the signiﬁcance of the potential
problem. The ability to quantify functional changes in RRF
during the ﬁrst year of HD, and in particular the residual urine
volume (RUV) production ability holds the prospect of
informing clinical practice by assisting clinicians to make
clinical decisions on regular treatment goals including rate of
ultraﬁltration (UF) and total ultraﬁltration goal (volume) prior
to each HD session. So far, previous research has only described
that RRF is declining in the ﬁrst year of HD (24), and little
evidence has been provided on how much the RRF is declining
and how much this might vary amongst individuals over time.

INTRODUCTION
Chronic kidney disease (CKD) is a condition where the function of
kidneys is diminished. In 2015, the global burden of the disease
(GBD) attributed 1.2 million deaths to kidney failure. The GBD
also estimated a further 1.2 million deaths and 18 million years of
life lost from cardiovascular conditions directly related to a
reduced glomerular ﬁltration rate (GFR) in the kidneys (1).
According to the Australian Bureau of Statistics (2), in 20172018 237,800 people in Australia (1% of the total population) were
suffering from CKD. The prevalence of this disease remained
unchanged with gender but increased with age (2). In 2017, one in
nine deaths were attributed to CKD being an underlying and or an
associated cause according to the Australian Institute of Health
and Welfare (3). In 2016-17, about 16% of all hospitalisations were
associated with CKD (3). Kidney and urinary diseases accounted
for 1.4% of all diseases in Australia in 2015 (3). Indigenous
Australians are 3.6% more likely to die from CKD than those of
non-indigenous descent (3).
Individuals with chronic kidney disease (CKD) require a form
of renal replacement therapy (RRT), either haemodialysis (HD),
peritoneal dialysis (PD) or a kidney transplant, when they reach
stage ﬁve of CKD (4). Traditionally, patients will start with RRT
when the glomerular ﬁltration rate (GFR) drops below 15mL/min/
1.73m2 and uremic symptoms of kidney disease prevail (5).
Haemodialysis sessions usually aim to restore ﬂuid balance by
removing excess ﬂuid via ultraﬁltration (UF) and remove
metabolic waste products through a convective solute
transport (6).
Residual renal function (RRF) in patients receiving dialysis is
the residual ability of the kidneys to produce urine and excrete
waste products, even when CKD persists. The importance of the
RRF for patients on maintenance HD for their survival has often
been emphasized (7–10). In addition to improved survival rates, a
positive impact on their quality of life has also been reported, when
RRF was present (11, 12). Further to this, the loss of RRF has also
been associated with vascular calciﬁcation in HD patients (13),
which can also have detrimental consequences on their health
(14). Additionally, events of intradialytic hypotension (IDH)
occurring while individuals undergo HD sessions have been
described as being detrimental to their RRF (15).
Understanding of the RRF status of an individual is not just
important for the extra clearance of harmful metabolites that
maybe necessary during regular HD sessions (16), but it may also
hold essential information about the daily urine volume. This in
turn may help to inform ﬂuid-related decision-making processes
from patients and clinicians alike. An individualised, patient
centred approach for the deﬁnition of treatment goals,
particularly in regard to UF and excess volume, accounting for
unique patient factors may prove to be beneﬁcial for patient
outcomes (17). While the knowledge of an individual’s current
RRF has the potential to inﬂuence treatment regimen and
treatment (UF) goals over time, it may also affect an individuals’
daily ﬂuid intake in between HD sessions and affect their healthrelated quality of life (HRQL) and interdialytic weight gain (18–
20). Knowledge of an individual’s RRF could potentially add
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AIM
This scoping review aims to provide evidence in peer-reviewed
published literature for the rate of functional decline in the urine
output of CKD patients starting with maintenance haemodialysis
during the ﬁrst 12 months of treatment. This information could
be useful to inform current clinical practice when patients
embark on haemodialysis as their ongoing treatment for CKD.
It could also potentially lead clinicians to implement novel
structural measures to protect their patients’ RRF from
functional decline in future. The following research question in
this scoping review is: “What is the functional decline in urine
production within the ﬁrst 12 months following commencement
of HD for end-stage renal disease (ESRD) and how does this
affect their quality of life or mortality?”
To facilitate the literature search, the clinical question was
addressed using the PICO framework with the following items:
Population: Adult CKD patients with ESRD, aged 18 years
and above on maintenance HD in hospitals and satellite dialysis
clinics were included, patients on home HD and pregnant
patients were excluded from the search, Intervention: HD,
Comparison: Residual Renal Output based on residual urine
output volume compared to patients with no residual urine
output, Outcomes: Quality of life, mortality.

METHODS
A scoping literature review was performed in 2021 to search for
peer-reviewed journal articles in medical and nursing journals.
The search mainly focused on residual renal function of patients
within the ﬁrst 12 months after haemodialysis initiation with
emphasis on the residual urine output volume. It was of
particular interest if residual urine output function provided a
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6 articles were found covering this topic which were either
Systematic Literature reviews or Systematic Literature reviews.
These articles are presented in Table 2.

speciﬁc survival advantage in comparison to individuals with
ESRD and no residual urine output. The databases used were
CINHAL Plus with Full Text, MEDLINE, Embase and Web of
Science. The search terms used included “residual renal
function” or “residual kidney function” (= Search term 1 or
S1) “haemodialysis initiation” (S2), “haemodialysis and urine
output or urine volume” (S3), and “residual renal function and
haemodialysis” (S3). The search terms S1, S2, S3 were combined
with the term “ﬁrst year of haemodialysis”. Journal articles
included in this scoping review were peer-reviewed, full text
articles, in English language and published between 2014 and
2021. Additionally, academic journals, renal registries, case
reports, non-randomized clinical trials, doctoral dissertations
and retrospective audits were included in the overall search.
Further, articles and reviews which did not meet minimum
quality requirements, without peer review or an abstract were
excluded from the review. A PRISMA checklist has been applied
to validate the results of this scoping review.

RESIDUAL RENAL FUNCTION DURING
THE FIRST YEAR OF HAEMODIALYSIS
Relevant literature concerning urine volume output of patients
receiving maintenance HD during their ﬁrst year on RRT was
examined. No articles quantifying HD patients’ declining urine
volume during this time period were found, however, several
papers have concluded that the RRF rapidly declines during the
ﬁrst year of maintenance HD. There was no further detailed
description of this declining RRF found in the current scientiﬁc
literature or describing speciﬁcally the RUV in this particular
patient cohort.
An observational study by (26) has concluded that a fast
decline in RRF in PD patients resulted in early withdrawal from
PD and conversion to HD treatment, as HD allows for more
precise excess volume management. On the other hand, large
volume removal (UF goals) during HD may have negative
consequences, such as IDH and subsequently a decline in RRF
(31). These authors concluded that frequent RRF measurements
are essential, as the frequency of HD treatments need to be
adjusted according to the patient’s RRF status.
A small observational study on seven HD patients by Sjolund,
Garcia Anton (28) in the Netherlands has reported that during
the ﬁrst six to 12 months of maintenance HD the mean urine
volume reduced at a rate of 1 ml per month. These authors
emphasized the beneﬁcial effects of loop diuretics on RRF as their
patients were concurrently treated with increasing doses of
furosemide during the ﬁrst 12 months of HD treatment and
suggested their use in all incident HD patients. According to
their conclusion, this seems to be not a commonly used approach
and may vary amongst HD centres globally.
A prospective multicentre study in the United States by You,
Kalantar-Zadeh (35) has concluded, that a large proportion of
patients commencing with HD have a substantial residual kidney
function including urine output and that “some data suggests
that haemodialysis patients experience greater preservation of
kidney function than previously estimated”. These authors have
also reported that sometimes 14-20% of patients still have some
RRF after three to ﬁve years after transitioning to HD.
Mokoli et al. (30) conducted a historical cohort study,
recruiting 250 patients with end stage renal disease (ESRD). The
study collected residual urine volume (RUV) over 24 hours at the
start, 6 months and 12 months of HD treatments. Patients who
had RUV of > 500 ml/day were mostly on diuretics, angiotensin
converting enzyme inhibitors (ACEI) with less hypovolemia,
hyperkalaemia and anaemia, with higher levels of serum
albumin (30), which could prove a survival beneﬁt and affect
mortality. The mean RUV values at HD initiation were 680 ±
537 ml/day, 558 ± 442 at 6 months and 499 ± 475 at 12 months.
Decreased urine volume levels were seen in all patients except in
patients who did not have any hypertension. Patients who were
male, hypovolemic, had chronic tubulointerstitial nephropathy

RESULTS
The primary search in all four databases resulted in 369 nonduplicate citations which were then screened (Figure 1). Applying
inclusion and exclusion criteria reduced the number of qualiﬁed
articles to 59. Another 104 articles were excluded during data
extraction, as they did not contain enough statistical data or were
as well not considered to be relevant to the research question of
residual urine output during the ﬁrst year of haemodialysis. This
scoping literature review resulted in a deﬁnitive number of 9
articles which met all characteristics of the inclusion criteria.
Table 1 presents a summary of these 15 articles.

FIGURE 1 | Results of scoping review by searching 4 databases (CINAHL
plus, MEDLINE, Embase, Web of Science, PRISMA ﬂowchart.
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TABLE 1 | Summary table of 9 articles: Decline of RRF and urine output volume during the ﬁrst year of HD.
Author (year), Title

Study design

Comments/key ﬁndings

Sample size and sites

1 Blum, D. (25) “Thinking Volume
First: Developing a Multifaceted
systematic approach to Volume
Management in Haemodialysis.”

Case study
presentation

16 patients
HD unit St Michael’s Hospital
(Canada)

2 Wang, J. et al. (26) “A fast
decline of residual renal function
in the ﬁrst year is a predictor for
early withdrawal from peritoneal
Dialysis in Non-diabetic
patients.”
3 Lee et al. (27) “Ultraﬁltration rate
effects declines in residual
kidney function in hemodialysis
patients.”
4 Obi et al. (9) “Residual kidney
function decline and mortality in
incident hemodialysis patients.”

Observational
study

567 patients at First Afﬁliated
Hospital Zhejiang (China) who
started with PD between 2005
and 2013

Retrospective
cohort study

7, 753 patients who initiated
conventional hemodialysis from
2007 to 2011 (United States)

Higher UFR was associated with a rapid decline in residual renal function
among conventional hemodialysis patients.

Longitudinal
study

6538 patients (2007 to 2010)
(California, United States)

5 Shaﬁ et al. (8) “Residual kidney
function: Implications in the era
of personalised medicine.”

Case study

(Amsterdam, Netherlands)

6 Silva et al. (20) “Coping with
ﬂuid restriction and the quality of
life in hemodialysis patients with
very low or no daily urine
output.”
7 Sjolund et al. (28) “Diuretics,
limited ultraﬁltration, and residual
renal function in incident
hemodialysis patients: A case
series.”
8 Poulsen et al. (29) “Quality of life
development during initial
haemodialysis therapy and
association with loss of residual
renal function.”

Cross
sectional
study

271 Brazilian adult maintenance
hemodialysis patients
(Brazil)

Only a few studies have explored RKF in patients on HD. RKF contributes to
adequate solute clearance. Data at baseline and 1 year after HD initiation
reported gradient association between RKF loss and all-cause mortality.
Clinical beneﬁts of RKF preservation methods are yet to be determined.
Residual kidney function is essential for improved outcomes of PD and HD.
After dialysis initiation, RKF provides volume and solute clearance necessary
to remove toxins that cannot be removed using conventional dialysis
methods. The management of uremia can be personalized due to the beneﬁts
of RKF, taking into account the solute, volume and quality of life needs.
52.4% of the participants reported being moderately to extremely bothered by
ﬂuid restriction and had lower scores for health-related quality of life. Increased
ﬂuid restriction decreases quality of life. An improvement in ﬂuid restriction
methods can improve quality of life in HD patients.

Case series

7 hemodialysis patients
(The Netherlands)

Questionnaire
(Kidney
Disease
Quality of Life
Short Form
Version 1.3)
Cohort study

82 patients at 6 months and 12
months of dialysis treatment
(Denmark)

9 Mokoli et al. (30) “Factors
associated with residual urine
volume preservation in patients
undergoing haemodialysis for
end-stage kidney disease in
Kinshasa.”

250 patients with ESRD
undergoing haemodialysis
between January 2007 and July
2013 in two haemodialysis
centres in Kinshasa, Democratic
Republic of Congo

During the ﬁrst 6 to 12 months the mean urine volume was reduced by 1ml
per month, residual GFR declined by 0.03 ml/min/1.72m2 /month. The mean
rate of decline for urine volume from 12 to 24 months was 33ml/month and
residual GFR was 0.02ml/min/1.72m2 /month. The low rate decline is due to
the effects of diuretic (frusemide) during the ﬁrst 2 years of HD initiation.
The use of Irbesartan did not affect Health Related Quality of Life (HRQL).
Decline in GFR correlated with decreased HRQL over time. Preservation of
residual renal function is important for HRQL, which is also negatively affected
by comorbidities such as diabetes, hospital admissions, female gender and
age.
ACE inhibitors, chronic tubulointerstitial nephropathy and left ventricular
hypertrophy reduction emerged as the main independent predictors of
residual urine volume preservation over time, and in particular in the ﬁrst year
of dialysis.

potential to aid in preserving residual kidney function in the
long term. Most clinics do not measure RRF due to the difﬁculty of
timed urine collection and therefore the patient does not receive
personalised HD prescription that may aid in the preservation of
RRF (37). Wong et al. (37) explored methods of measuring RRF
without urine collection. The study concluded that timed urine
collections can be very challenging and instead the use of
biomarkers to determine cut off levels of residual urea clearance
may be a better and promising method. You, Kalantar-Zadeh (35)
have reported correspondingly that frequently measuring 24-hour
urine collection is onerous and assessment of patient-reported
urine volume may help in the day-to day management of HD and
can be easily implemented at the patient’s bedside.

and those who were treated with diuretics and ACEI and
angiotensin receptor blockers (ARB) had a higher median urine
volume (36). The study concluded that RRF declines over 12
months of HD treatments. Preservation of RRF was signiﬁcantly
associated with ACEI and interstitial nephropathy. On the other
hand, the loss of RRF was associated with the presence of left
ventricular hypertrophy (LVH) at the initiation of HD treatments
(36). The main limitation in this study was the relatively small
sample size and the retrospective characteristics that hindered
setting up a cause-effect relationship. Despite the limitations, this
study is one of the few that has used RUV collections to measure
the decline in RRF over 12 months of HD treatments. The
incorporation of the RRF into the HD prescriptions has
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Local volume management with 3 components
Volume metric reporting integrated into the routine bloodwork reports.
Abnormal metrics were evaluated using technological testing in the form of
lung ultrasound and bioimpedance spectrometry. Patients with abnormal
metrics for volume were reviewed and educated by the multidisciplinary team.
Faster RRF decline in the ﬁrst year was a predictor for all-cause mortality and
conversion to HD in non-diabetic PD patients
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TABLE 2 | Summary table of 6 articles, either Literature Reviews or Systematic Literature reviews: Decline of RRF and urine output volume during the ﬁrst year of HD.
Author (year), Title

Study design

1 Huang, S. et al. (31)
“Euvolemia in haemodialysis
patients: A potentially
dangerous goal?”
2 Kong, Davies, & Mount (24)
“The importance of residual
kidney function in dialysis
patients.”
3 Mathew, A.T. (17) “Incremental
dialysis for preserving residual
kidney function: Does one size
ﬁt all when initiating dialysis?”

Literature
review

12 articles (1999 to
2016) (United
Kingdom)

Systematic
literature review

Articles from 2017 to
2018 (Victoria,
Australia)

Literature
review

12 observational
cohort studies
(California, United
States)

4 OK et al. (32) “Interplay of
volume, blood pressure, organ
ischemia, residual renal
function, and diet: Certainties
and uncertainties with dialytic
management.”
5 Mitema & Jaar (33) “How can
we improve the quality of life of
dialysis patients.”

Literature
review

(Turkey)

Literature
review: review
of various
Health-Related
Quality of Life
(HRQOL) tools
Systematic
Literature
review

(United States)

6 Fang et al. (34) “Residual renal
function among patients on
haemodialysis and implications
for clinical practice.”

comments/key ﬁndings

Sample size and sites

4 databases searched
for relevant information
between 200 and 2018
(Medline, CINAHL Plus,
Embase and Pubmed)

Patient characteristics such as RRF, adequate volume control, lack of signiﬁcant
anaemia/electrolyte imbalance, satisfactory health related quality of life, low comorbid
disease burden, and good nutritional status. Regular RRF measurements is essential,
because HD frequency needs to be adjusted depending on the patient’s RRF status.
Over 80% of patients have some levels of residual renal function present at the start of
dialysis treatments. There is a decline over the years, however, up to 30% of patients
after 5 years of HD still have a measurable level of RRF. In HD patients, RRF is usually
disregarded. To maintain and maximize RRF in HD patients, further research is needed.
Haemodialysis is usually initiated on 3 times per week, regardless of residual kidney
function. As RKF is associated with numerous beneﬁts for the patients, it is essential for
HD treatments to be personalized, taking into account the individual RKF. Incremental
HD prescriptions are recommended in this case, as HD initiation is less frequent and
allows for regular measurement of RKF.
Both blood pressure and volume control are managed poorly in HD patients which
causes the increased morbidity and mortality. Restriction of dietary salt intake, increased
frequency, and/or duration of haemodialysis sessions or addition of temporary extra
sessions during the process of gradually reducing post- dialysis body weight in
conventional HD and discontinuation of antihypertensive medications could prevent
these complications.
There are multiple validated tools which can be used to improve HRQOL in ESRD
patients. Each tool should be used in an individualized manner to address speciﬁc
dialysis patient needs such as anaemia, depression sexual dysfunction, sleep related
disorders and the preservation of residual kidney function.

Nephrology nurses can improve clinical practice to assist preserving RKF in HD patients
through preventing intradialytic hypotension, improving dry weight assessment and
volume control, advocating for incremental HD, promoting haemodiaﬁltration and other
measures

a decreased quality of life. The lower HRQOL is associated with
increased restrictions in diet, ﬂuids, and the duration of dialysis
sessions as the RRF declines (18, 20). Kong, Davies and Mount
(24) conducted a literature review to explore the relationship
between RRF and the outcomes for patients on HD treatment.
The study found that the preservation of RRF, even at very low
levels, contributes to increased quality of life and patient
survival (24).

QUALITY OF LIFE AND RESIDUAL
RENAL FUNCTION
Another major factor in the discussion about RRF is its impact
on the Quality of Life (QOL) in HD patients. A publication by
Mitema and Jaar (33) has investigated a variety of validated tools
which are readily available to assess HD patients QOL. They have
recommended to use each tool in an individualized manner to
address speciﬁc patient needs and recommended to include the
preservation of the RRF. These authors also reported from
patients with self-reported urine output at baseline of at least
250 ml/day were reporting better social functioning, vitality,
cognitive functioning and quality of life over a year. Poulsen et al.
(18) surveyed 82 HD patients using the Kidney Disease Quality
of Life Short Form Version 1.3 (KDQOL-SFTM) at the start of
treatment, at six and 12 months. The study concluded that health
related quality of life (HRQOL) is largely impacted in patients
receiving HD treatment. Although the patient can become used
to the HD and this could lead to an improved HRQOL. However,
other debilitating factors such as multiple side effects of HD,
frequent hospitalisation, diabetes and the decline in RRF after 12
months can eventually lead to a further decrease in HRQOL (18).
Decreasing glomerular ﬁltration rate (GFR) was measured by
collecting urine for 24 hours at baseline, 6 and 12 months in this
study. A decreasing GFR in patients with CKD also lowers
HRQOL, was concluded by these authors. Other studies have
found a marked correlation between decreased urine volume and

Frontiers in Nephrology | www.frontiersin.org

RESIDUAL RENAL FUNCTION
PRESERVATION
In a longitudinal cohort of 6538 patients, Obi et al. (9) aimed to
determine the existing clinical factors at HD initiation that predict
the preservation of RRF at 1 year of HD treatments. The study
also included quantitative investigations of the association in the
annual change of RRF with survival. The study found that greater
renal urine clearance (CLurea) after 1 year of HD treatments,
which lead to better survival rates. Factors such as being female,
non-white races, history of congestive heart failure (CHF) and
diabetes were the main factors which were associated with RRF
decline in the ﬁrst year of HD (9). The median baseline urine
volume was 900 ml/day and the median volume at 1 year was 650
ml/day. These authors also observed a signiﬁcant trend toward
lower mortality at higher urine volume. Several limitations existed
in this study with the most important one being the inaccuracy of
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personalise HD treatments and improve volume status in
patients (25). The study had several limitations including the
tracking of the patients in 6-week intervals and not in real time
and the use of recommended technological adjuncts being
limited to the availability of trained staff (25). A recent multicentre randomized controlled trial study by (41) has
demonstrated the efﬁcacy of a lung ultrasound-guided
treatment strategy when assessing patients for ﬂuid overload
and determining ultraﬁltration goals. This highlights the need for
qualiﬁed and appropriately trained healthcare professionals,
which potentially will be in most situations the renal nurses
who are caring for HD patients attending their treatments.
HD has often been described as being associated with being
more successful in attaining euvolemia than PD, but also with a
more rapid loss of residual renal function (42) which may be
detrimental for the patient’s survival (8).
A study by Lee, Okuda (27) has indicated that a higher
ultraﬁltration rate (UFR), which equals the ultraﬁltration in
millilitres per hour of HD treatment, has been observed as
associated with rapid decline in RRF and also increased
mortality among conventional HD patients. It can therefore be
assumed that the lower the UFR is, the less detrimental effect the
UFR may have on the RUV in the long term.

RRF measurements, using the (CLurea) instead of the average
renal urea and creatinine clearance. Complete urine collection
samples were also challenging in terms of timing. Patients who
were treated with PD, nocturnal HD or Home HD were excluded
from the study although they might have had presented with
different RRF (9).
In HD patients, RRF can contribute to removal of sodium and
improved volume control, leading to a reduced interdialytic weight
gain. Left ventricular hypertrophy and left ventricular systolic
dysfunction are less severe with the presence of RRF. Residual
renal function is also associated with higher serum albumin and
correlates to a better nutritional status in HD patients (24, 38).
Mathew et al. (17) have emphasized the importance of regular
RRF measurements in order to allow the use of incremental HD in
case of a decline in RRF. The difﬁculty in accurate measurement of
the interdialytic urine levels is thought to be the main reason that
only 5% of HD patients have measured RRF levels. Higher RRF at
one year of dialysis has been associated with higher survival rates
(17). Studies have suggested the preservation of RRF may be
possible with a twice weekly HD regimen, compared to the routine
thrice weekly which was associated with a loss of RRF that was
seven times higher (17, 39).
A systematic literature review by Fang, Lunardi (34) has
indicated that renal nurses have multiple options to improve
clinical practice which may assist in preserving RRF in HD
patients through a variety of measures. This includes the
prevention of intradialytic hypotension, improving measures for
dry weight or ideal body weight assessments, volume control,
advocating for incremental HD, promoting haemodiaﬁltration
(HDF) as a treatment option and other measures.

IMPLICATIONS FOR PRACTICE
• Renal nurses are the primary healthcare professionals caring
for patients starting on maintenance HD and must be made
aware and receive more speciﬁc education about the
importance of maintaining RRF and RUV in HD patients,
speciﬁcally during the ﬁrst year on HD
• Regular RUV measurements in patients starting with HD may
hold essential information to inform clinicians when deciding
on regular treatment (UF) goals
• Knowledge of the individual parameters of RUV may have
positive implications for HRQOL and provide better health
outcomes for HD patients starting with HD
• Increasing doses of loop diuretics during the ﬁrst year of HD,
such as furosemide, may be preservative for the RRF
and RUV.
• Observing of patient-reported urine volume may provide for
better ﬂuid management and may support preserving RRF
and RUV in patients on HD.

DISCUSSION
In the HD population, volume overload and hypovolemia
are common debilitating symptoms which can increase
hospitalisation, leading to a reduced quality of life (25).
Volume overload can cause cardiovascular events, dyspnoea
and left ventricular remodelling which can eventually lead to
death (40). Hypovolemia on the other hand causes organ
ischemia, fatigue and changes in cognitive functioning (25, 32)
while organ ischemia may subsequently lead to loss of residual
renal function (32). Blum et al. (25) suggested three main volume
management strategies that will help clinicians determine
patient’s true volume status. The ﬁrst strategy was to integrate
the reporting of volume metric into the routine bloodwork
report. The use of technology such as bioimpedance and lung
ultrasound along with traditional tests can aid in volume
assessment and review and assessment of abnormal volume
metrics by the multidisciplinary team. The study identiﬁed 16
patients with abnormal volume metrics where the volume
dysfunction was related to either a high intradialytic weight
gain, incorrect target weight gain or missed sessions of HD
treatment (25). The patients were tracked at 6-week intervals
with the goal of reducing the prevalence of abnormal volume
metrics by targeting the root causes. The study concluded that
the use of the three volume management strategies can
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CONCLUSION
This literature review has demonstrated, that preserving RRF and
RUV for as long as possible has multiple positive implications on
the health-related quality of life (HRQOL) and on the morbidity
in HD patients. This is essential and important, especially the
longer this RRF is maintained. No study was found which had
either observed, documented, or quantiﬁed the loss of RUV in a
detailed description over the ﬁrst 12 months of maintenance HD
and/or any correlation to goals of treatment in terms of removal
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TABLE 3 | Potential future studies resulting from this scoping review.
An observational study on the functional decrease of the renal residual
function including urine production in haemodialysis patients during
their ﬁrst year of treatment
An observational study on the current clinical practices and methods
of ﬂuid assessment and ultraﬁltration goals in haemodialysis units
What is the current clinical practice of renal nurses in terms of
preserving the renal residual function in patients on haemodialysis – An
observational study
Which factors may cause the decline of the renal residual function and
the urine production in haemodialysis patients?

about the importance of maintaining renal residual function in
patients receiving haemodialysis, speciﬁcally during the patient’s
ﬁrst year on haemodialysis. This may affect health outcomes for
this patient cohort positively and may have potential to result in
a prolonged renal residual function for these patients.
The following table (Table 3) depicts potential future studies
resulting from this scoping review.

Study 1

Study 2
Study 3

Study 4
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